- Home
- TBI vs SGMO Comparison
TBI vs SGMO Comparison
Compare TBI & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBI | SGMO |
|---|---|---|
| Founded | 1985 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.9M | 131.2M |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TBI | SGMO |
|---|---|---|
| Price | $4.54 | $0.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $5.75 |
| AVG Volume (30 Days) | 183.6K | ★ 8.5M |
| Earning Date | 02-18-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,583,772,000.00 | $32,875,000.00 |
| Revenue This Year | $3.80 | $4.79 |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.45 | $0.35 |
| 52 Week High | $7.86 | $1.24 |
Technical Indicators
Market Signals| Indicator | TBI | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 45.63 |
| Support Level | $4.50 | $0.37 |
| Resistance Level | $5.70 | $0.40 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 12.92 | 15.69 |
Price Performance
Historical ComparisonAbout TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.